Syndax Pharmaceuticals, Inc. (SNDX)

Market Cap	1.13B
Revenue (ttm)	23.68M
Net Income (ttm)	-318.76M
Shares Out	86.02M
EPS (ttm)	-3.72
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	803,815
Open	13.69
Previous Close	13.56
Day's Range	12.95 - 13.80
52-Week Range	12.06 - 25.07
Beta	0.92
Analysts	Strong Buy
Price Target	36.20 (+174.66%)
Earnings Date	Mar 3, 2025

About SNDX

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are Revuforj, a menin inhibitor, which has completed phase 2 clinical trial for the treatment of relapsed or refractory and acute leukemia. The company is revumenib for R/R mNPM1 AML and studying the use of revumenib in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia across the treatment landscape, including in newly diagnosed patients. It also developing Niktimvo...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 3, 2016
• Employees: 270
• Stock Exchange: NASDAQ
• Ticker Symbol: SNDX
• Website: https://www.syndax.com

Analyst Forecast

According to 10 analysts, the average rating for SNDX stock is "Strong Buy." The 12-month stock price forecast is $36.2, which is an increase of 174.66% from the latest price.

Price Target

$36.2

(174.66% upside)

Analyst Consensus: Strong Buy